| Price differentiation and transparency in the global pharmaceutical marketplace. | |
| | |
MedLine Citation:
|
PMID: 15987224 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Pharmaceutical manufacturers have increased the availability of their products and sometimes increased their own financial returns by charging lower prices outside of the US and by discounting to lower-income patients in the US. Examples include discounted HIV-AIDS drugs in developing countries and pharmaceutical manufacturers' discount cards in the US. Representatives of some international organisations argue that the price reductions are insufficient to make the medications widely available to lower-income patients. The WHO advocates both differential pricing and price transparency. While its efforts are well meaning, this paper identifies six concerns about its methods of comparing the price of a given molecule across manufacturers and across countries. More significantly, the WHO efforts to increase transparency are likely to lead to less price differentiation and less access to innovative pharmaceuticals. An important reason why manufacturers are reluctant to charge lower prices in lower-income countries is that they fear that such low prices will undermine the prices they charge to higher-income consumers. International organisations should not facilitate transparency but should dissuade governments from making price comparisons and basing their prices on those of lower-income countries. Furthermore, they should endeavour to keep low-priced and free drugs in the hands of the low-income consumers for which they were intended. |
| | |
Authors:
|
David B Ridley |
Related Documents
:
|
15788994 - Progress toward poliomyelitis eradication--afghanistan and pakistan, january 2004-febru... 17002194 - What drives donor funding in population assistance programs? evidence from oecd countries. 1878404 - The development of a community-based hiv/aids counselling service in a rural area in ug... 3660154 - Sex and infertility. part i. prevalence of psychosexual problems and subjacent factors. 12630274 - Building young people's public lives: one foundation's strategy. 21513674 - Using a cross-study design to assess the efficacy of motivational enhancement therapy-c... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: PharmacoEconomics Volume: 23 ISSN: 1170-7690 ISO Abbreviation: Pharmacoeconomics Publication Date: 2005 |
Date Detail:
|
Created Date: 2005-06-30 Completed Date: 2005-10-07 Revised Date: 2009-11-03 |
Medline Journal Info:
|
Nlm Unique ID: 9212404 Medline TA: Pharmacoeconomics Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 651-8 Citation Subset: T |
Affiliation:
|
The Fuqua School of Business, Duke University, Durham, North Carolina, USA. david.ridley@duke.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cost Control Costs and Cost Analysis Drug Costs* Drug Industry / economics* International Cooperation Marketing* Patents as Topic Prescription Fees* World Health Organization |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Catalytic Synthesis of gamma-Lactams via direct annulations of enals and N-sulfonylimines.
Next Document: Evaluating health-related quality-of-life studies in paediatric populations: some conceptual, method...